Intra-Cellular Therapies Ownership | Who Owns Intra-Cellular Therapies?

Overview Forecast RevenueFinancials Chart Transcripts

Intra-Cellular Therapies Ownership Summary

Intra-Cellular Therapies is owned by 88.67% institutional investors, 2.33% insiders, and 9.00% retail investors. Fmr is the largest institutional shareholder, holding 11.60% of ITCI shares. Fidelity Growth Compy Commingled Pl O is the top mutual fund, with 3.69% of its assets in Intra-Cellular Therapies shares.

ITCI Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Intra-Cellular Therapies	88.67%	2.33%	9.00%
Sector	Healthcare Stocks	49.73%	8.84%	41.43%
Industry	Specialty & Generic Drug Manufacturers Stocks	34.90%	10.53%	54.58%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Fmr	11.24M	11.60%	$769.68M
Vanguard group	9.61M	9.92%	$657.98M
Blackrock	6.32M	6.53%	$432.97M
Wasatch advisors lp	3.72M	3.84%	$254.66M
Jpmorgan chase	3.44M	3.55%	$235.28M
Avoro capital advisors	3.00M	3.10%	$205.47M
Invesco	2.94M	3.03%	$201.18M
Bellevue group	2.47M	2.55%	$169.26M
Norges bank	1.94M	2.01%	$133.13M
State street	1.80M	1.86%	$123.44M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Altium capital management lp	193.00K	5.39%	$13.22M
Suvretta capital management	1.57M	3.94%	$107.26M
First turn management	347.34K	3.87%	$23.79M
Dcf advisers	100.51K	3.55%	$6.88M
Silverarc capital management	192.34K	3.11%	$13.17M
Artia global partners lp	216.52K	2.87%	$14.83M
Perceptive advisors	1.72M	2.79%	$117.56M
Bellevue group	2.47M	2.75%	$169.26M
Avoro capital advisors	3.00M	2.74%	$205.47M
Tang capital management	300.00K	2.09%	$20.55M

Top Buyers

Holder	Shares	% Assets	Change
Norges bank	1.94M	0.02%	1.94M
Jpmorgan chase	3.44M	0.02%	1.68M
Alyeska investment group	1.39M	0.55%	1.14M
Westfield capital management co lp	1.04M	0.35%	1.04M
Invesco	2.94M	0.04%	864.37K

Top Sellers

Holder	Shares	% Assets	Change
Blackrock	6.32M	0.01%	-1.76M
Avidity partners management lp	-	-	-600.00K
Macquarie group	1.01M	0.08%	-451.11K
State street	1.80M	0.01%	-438.44K
Wellington management group llp	1.25M	0.02%	-408.97K

New Positions

Holder	Shares	% Assets	Change	Value
Norges bank	1.94M	0.02%	1.94M	$133.13M
Westfield capital management co lp	1.04M	0.35%	1.04M	$71.43M
Hood river capital management	487.52K	0.69%	487.52K	$33.39M
Driehaus capital management	215.44K	0.14%	215.44K	$14.76M
Moody aldrich partners	99.01K	1.32%	99.01K	$6.78M

Sold Out

Holder	Change
Sanctuary wealth management	-1.00
Financial gravity asset management	-1.00
Continuum advisory	-6.00
Financial synergies wealth advisors	-6.00
International assets investment management	-12.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	361	-5.99%	93,782,613	-2.67%	88	1.03%	176	-18.14%	126	-0.79%
Jun 30, 2024	378	3.00%	96,330,666	10.68%	99	1.21%	210	19.32%	127	-
Mar 31, 2024	367	5.16%	87,032,607	-2.57%	90	1.05%	176	-3.83%	127	11.40%
Dec 31, 2023	349	15.95%	89,328,831	3.75%	92	1.15%	183	12.96%	114	26.67%
Sep 30, 2023	301	1.69%	86,097,281	2.30%	89	1.15%	162	-1.82%	90	11.11%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Fidelity Growth Compy Commingled Pl O	3.90M	3.69%	-95.00K
Fidelity Growth Compy Commingled Pl S	3.89M	3.67%	-14.37K
Vanguard Total Stock Mkt Idx Inv	3.20M	3.02%	-13.99K
Fidelity Growth Company Fund	2.88M	2.71%	-45.39K
Vanguard Small Cap Index	2.52M	2.37%	4.95K
BB Biotech AG Ord	2.47M	2.34%	20.00K
Vanguard Institutional Extnd Mkt Idx Tr	1.47M	1.38%	-10.55K
Vanguard Small Cap Growth Index Inv	1.38M	1.30%	-3.79K
JPM US Mid Cap Growth-Composite	1.32M	1.25%	137.29K
JPMorgan Mid Cap Growth I	1.32M	1.24%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Dec 05, 2024	Mates Sharon	Chairman and CEO	Sell	$129.91K
Dec 04, 2024	Mates Sharon	Chairman and CEO	Sell	$2.01M
Dec 04, 2024	Mates Sharon	Chairman and CEO	Sell	$2.37M
Dec 05, 2024	Mates Sharon	Chairman and CEO	Sell	$4.22M
Nov 12, 2024	Halstead Michael	President	Sell	$149.79K

Insider Transactions Trends

Date	Buy	Sell
2024 Q4	-	9
2024 Q3	-	17
2024 Q2	-	3
2024 Q1	-	73
2023 Q4	-	5

ITCI Ownership FAQ

Who Owns Intra-Cellular Therapies?

Intra-Cellular Therapies shareholders are primarily institutional investors at 88.67%, followed by 2.33% insiders and 9.00% retail investors. The average institutional ownership in Intra-Cellular Therapies's industry, Specialty & Generic Drug Manufacturers Stocks, is 34.90%, which Intra-Cellular Therapies exceeds.

Who owns the most shares of Intra-Cellular Therapies?

Intra-Cellular Therapies’s largest shareholders are Fmr (11.24M shares, 11.60%), Vanguard group (9.61M shares, 9.92%), and Blackrock (6.32M shares, 6.53%). Together, they hold 28.04% of Intra-Cellular Therapies’s total shares outstanding.

Does Blackrock own Intra-Cellular Therapies?

Yes, BlackRock owns 6.53% of Intra-Cellular Therapies, totaling 6.32M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 432.97M$. In the last quarter, BlackRock decreased its holdings by -1.756M shares, a -21.74% change.

Who is Intra-Cellular Therapies’s biggest shareholder by percentage of total assets invested?

Altium capital management lp is Intra-Cellular Therapies’s biggest shareholder by percentage of total assets invested, with 5.39% of its assets in 193K Intra-Cellular Therapies shares, valued at 13.22M$.

Who is the top mutual fund holder of Intra-Cellular Therapies shares?

Fidelity Growth Compy Commingled Pl O is the top mutual fund holder of Intra-Cellular Therapies shares, with 3.69% of its total shares outstanding invested in 3.9M Intra-Cellular Therapies shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools